Vivoryon Therapeutics N.V. (0R3M.L)

EUR 1.77

(-0.56%)

Total Debt Summary of Vivoryon Therapeutics N.V.

  • Vivoryon Therapeutics N.V.'s latest annual total debt in 2023 was 38 Thousand EUR , down -71.21% from previous year.
  • Vivoryon Therapeutics N.V.'s latest quarterly total debt in 2024 Q2 was 10 Thousand EUR , down 0.0% from previous quarter.
  • Vivoryon Therapeutics N.V. reported annual total debt of 132 Thousand EUR in 2022, down -41.07% from previous year.
  • Vivoryon Therapeutics N.V. reported annual total debt of 224 Thousand EUR in 2021, down -28.66% from previous year.
  • Vivoryon Therapeutics N.V. reported quarterly total debt of 38 Thousand EUR for 2023 Q4, down 0.0% from previous quarter.
  • Vivoryon Therapeutics N.V. reported quarterly total debt of 85 Thousand EUR for 2023 Q2, down 0.0% from previous quarter.

Annual Total Debt Chart of Vivoryon Therapeutics N.V. (2023 - 2010)

Historical Annual Total Debt of Vivoryon Therapeutics N.V. (2023 - 2010)

Year Total Debt Total Debt Growth
2023 38 Thousand EUR -71.21%
2022 132 Thousand EUR -41.07%
2021 224 Thousand EUR -28.66%
2020 314 Thousand EUR -22.66%
2019 406 Thousand EUR 0.0%
2018 - EUR 0.0%
2017 - EUR 0.0%
2016 - EUR 0.0%
2015 - EUR 0.0%
2014 - EUR -100.0%
2013 5.34 Million EUR 0.0%
2012 - EUR 0.0%
2011 - EUR 0.0%
2010 - EUR 0.0%

Peer Total Debt Comparison of Vivoryon Therapeutics N.V.

Name Total Debt Total Debt Difference
Boiron SA 13.7 Million EUR 99.723%
Laboratorios Farmaceuticos Rovi, S.A. 46.63 Million EUR 99.919%
Vetoquinol SA 17.62 Million EUR 99.784%
Valneva SE 208.81 Million EUR 99.982%
AB Science S.A. 19.1 Million EUR 99.801%
Nanobiotix S.A. 45.48 Million EUR 99.916%
PHAXIAM Therapeutics S.A. 10.19 Million EUR 99.627%
BioSenic S.A. 28.16 Million EUR 99.865%
ABIVAX Société Anonyme 55.46 Million EUR 99.931%
Formycon AG 29.48 Million EUR 99.871%